# Intravitreal Bevacizumab for Management of Active Progressive Proliferative Diabetic Retinopathy (PDR)

> **NCT00370721** · PHASE3 · UNKNOWN · sponsor: **Shahid Beheshti University of Medical Sciences**

## Conditions studied

- Diabetic Retinopathy

## Interventions

- **DRUG:** bevacizumab

## Key facts

- **NCT ID:** NCT00370721
- **Lead sponsor:** Shahid Beheshti University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-03
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2008-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00370721

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00370721, "Intravitreal Bevacizumab for Management of Active Progressive Proliferative Diabetic Retinopathy (PDR)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00370721. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*